Evidence map›Paper›PMID 27824162›Full record

Trial reportScientific reports2016

Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.

Sigve Andersen, Elin Richardsen, Line Moi, Tom Donnem, Yngve Nordby, Nora Ness, Marte Eilertsen Holman, Roy M Bremnes, Lill-Tove Busund

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sigve AndersenTranslational Cancer Research Group, Dept Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Elin RichardsenTranslational Cancer Research Group, Dept of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Line MoiTranslational Cancer Research Group, Dept of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Tom DonnemTranslational Cancer Research Group, Dept Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Yngve NordbyTranslational Cancer Research Group, Dept Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Nora NessTranslational Cancer Research Group, Dept of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Marte Eilertsen HolmanTranslational Cancer Research Group, Dept Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Roy M BremnesTranslational Cancer Research Group, Dept Clinical Medicine, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
Lill-Tove BusundTranslational Cancer Research Group, Dept of Medical Biology, UiT, The Arctic University of Norway, 9037 Tromso, Norway.
UiT The Arctic University of Norway · NOUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a need for better prognostication in prostate cancer (PC). "The micromanager of hypoxia", microRNA-210 (miR-210) is directly linked to hypoxia, is overexpressed in PC and has been implied in tumor cell-fibroblast crosstalk. We investigated the prognostic impact of miR-210 in tumor cells and fibroblasts in PC. Tumor and stromal samples from a multicenter PC cohort of 535 prostatectomy patients were inserted into tissue microarrays. To investigate the expression of miR-210, we used in situ hybridization and two pathologists semiquantitatively scored its expression. Overexpression of miR-210 in tumor cells was not associated to biochemical failure-free survival (BFFS, p = 0.85) or clinical failure-free survival (CFFS, p = 0.09). However, overexpression of miR-210 in fibroblasts was significantly associated to a poor CFFS (p = 0.001), but not BFFS (p = 0.232). This feature was validated in both cohorts. Overexpression of miR-210 was independently associated with a reduced CFFS (HR = 2.76, CI 95% 1.25-6.09, p = 0.012). Overexpression of miR-210 in fibroblasts is independently associated with a poor CFFS. This highlights the importance of fibroblasts and cellular compartment crosstalk in PC. miR-210 is a candidate prognostic marker and potential therapeutic target in PC.

Indexed as

Gene Expression Regulation, NeoplasticAgedDisease-Free SurvivalFibroblastsHumansIn Situ HybridizationMaleMicroRNAsMiddle AgedProstatic NeoplasmsRNA, NeoplasmSurvival RateMicroRNAsMIRN210 microRNA, humanRNA, Neoplasm

Identifiers

PMID27824162
PMCPMC5099893
OpenAlexW2550094225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.